A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder

Logan K Wink, Ryan Adams, Zemin Wang, James E Klaunig, Martin H Plawecki, David J Posey, Christopher J McDougle, Craig A Erickson, Logan K Wink, Ryan Adams, Zemin Wang, James E Klaunig, Martin H Plawecki, David J Posey, Christopher J McDougle, Craig A Erickson

Abstract

Background: Social impairment is a defining feature of autism spectrum disorder (ASD) with no demonstrated effective pharmacologic treatments. The goal of this study was to evaluate efficacy, safety, and tolerability of oral N-acetylcysteine (NAC), an antioxidant whose function overlaps with proposed mechanisms of ASD pathophysiology, targeting core social impairment in youth with ASD.

Methods: This study was a 12-week randomized, double-blind, placebo-controlled trial of oral NAC in youth with ASD. Study participants were medically healthy youth age 4 to 12 years with ASD, weighing ≥15 kg, and judged to be moderately ill based on the Clinical Global Impressions Severity scale. The participants were randomized via computer to active drug or placebo in a 1:1 ratio, with the target dose of NAC being 60 mg/kg/day in three divided doses. The primary outcome measure of efficacy was the Clinical Global Impressions Improvement (CGI-I) scale anchored to core social impairment. To investigate the impact of NAC on oxidative stress markers in peripheral blood, venous blood samples were collected at screen and week 12.

Results: Thirty-one patients were enrolled (NAC = 16, placebo = 15). Three participants were lost to follow-up, and three left the trial due to adverse effects. The average daily dose of NAC at week 12 was 56.2 mg/kg (SD = 9.7) with dose ranging from 33.6 to 64.3 mg/kg. The frequency of adverse events was so low that comparisons between groups could not be conducted. At week 12, there was no statistically significant difference between the NAC and placebo groups on the CGI-I (p > 0.69) but the glutathione (GSH) level in blood was significantly higher in the NAC group (p < 0.05). The oxidative glutathione disulfide (GSSG) level increased in the NAC group, however only at a trend level of significance (p = 0.09). There was no significant difference between the NAC and placebo groups in the GSH/GSSG ratio, DNA strand break and oxidative damage, and blood homocysteine levels at week 12 (ps > 0.16).

Conclusions: The results of this trial indicate that NAC treatment was well tolerated, had the expected effect of boosting GSH production, but had no significant impact on social impairment in youth with ASD.

Trial registration: Clinicaltrials.gov NCT00453180.

Keywords: Autism; Autism spectrum disorder; N-acetylcysteine; Oxidative stress; Social impairment.

References

    1. Kanner L. Autistic disturbances of affective contact. Nerv Child. 1943;2:217–50.
    1. Reichow B, Steiner AM, Volkmar F. Cochrane review: social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD) Evidence-based child health : a Cochrane review journal. 2013;8(2):266–315. doi: 10.1002/ebch.1903.
    1. Autism Spectrum Disorder, Data and Statistics []. Accessed 4/3/2016.
    1. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, Cutler P, Bock K, Boris M, Bradstreet JJ, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(8):947–56. doi: 10.1002/ajmg.b.30366.
    1. Erickson CA, Posey DJ, Stigler KA, McDougle CJ. Glutamatergic function in autism. In: Heresco-Levy U, editor. Glutamate in Neuropsychiatric Disorders. Trivandrum: Research Signpost; 2008. pp. 197–212.
    1. Kern JK, Jones AM. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health B Crit Rev. 2006;9(6):485–99. doi: 10.1080/10937400600882079.
    1. James SJ, Rose S, Melnyk S, Jernigan S, Blossom S, Pavliv O, Gaylor DW. Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J. 2009;23(8):2374–83. doi: 10.1096/fj.08-128926.
    1. Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O, Spielholz C, Frye R. Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review. Neurosci Biobehav Rev. 2015;55:294–321. doi: 10.1016/j.neubiorev.2015.04.015.
    1. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol. 1988;34(1):77–82. doi: 10.1007/BF01061422.
    1. Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav. 2014;4(2):108–22. doi: 10.1002/brb3.208.
    1. Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013;34(3):167–77. doi: 10.1016/j.tips.2013.01.001.
    1. Aman MG, Singh NN, Stewart AW, Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;5:485–91.
    1. Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, Frazier TW, Tirouvanziam R. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956–61. doi: 10.1016/j.biopsych.2012.01.014.
    1. Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry. 2013;13:196. doi: 10.1186/1471-244X-13-196.
    1. Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S. N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol. 2015;38(1):11–7. doi: 10.1097/WNF.0000000000000063.
    1. Ghanizadeh A, Derakhshan N. N-acetylcysteine for treatment of autism, a case report. J Res Med Sci. 2012;17(10):985–7.
    1. Marler S, Sanders KB, Veenstra-VanderWeele J. N-acetylcysteine as treatment for self-injurious behavior in a child with autism. J Child Adolesc Psychopharmacol. 2014;24(4):231–4. doi: 10.1089/cap.2013.0137.
    1. Melnyk S, Fuchs GJ, Schulz E, Lopez M, Kahler SG, Fussell JJ, Bellando J, Pavliv O, Rose S, Seidel L, et al. Metabolic imbalance associated with methylation dysregulation and oxidative damage in children with autism. J Autism Dev Disord. 2012;42(3):367–77. doi: 10.1007/s10803-011-1260-7.
    1. Guy W. ECDEU assessment manual for psychopharmacology, Publication No. 76-338. Washington: U.S. DHEW, NIMH; 1976.
    1. American, Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. Washington: American Psychiatric Press; 1994.
    1. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659–85. doi: 10.1007/BF02172145.
    1. Roid G, Miller L. Leiter International Performance Scale—revised. Wood Dale: Stoelting Company; 1997.
    1. Constantino J, Gruber C. Social Responsiveness Scale. 2005.
    1. Sparrow S, Cicchetti D, Balla DA. Vineland Adaptive Behaviors Scales. 2008.
    1. Research Units on Pediatric Psychopharmacology Autism N Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–321. doi: 10.1056/NEJMoa013171.
    1. McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry. 2005;162(6):1142–8. doi: 10.1176/appi.ajp.162.6.1142.
    1. Buxbaum JD, Bolshakova N, Brownfeld JM, Anney RJ, Bender P, Bernier R, Cook EH, Coon H, Cuccaro M, Freitag CM, et al. The Autism Simplex Collection: an international, expertly phenotyped autism sample for genetic and phenotypic analyses. Molecular autism. 2014;5:34. doi: 10.1186/2040-2392-5-34.
    1. Melnyk S, Pogribna M, Pogribny I, Hine RJ, James SJ. A new HPLC method for the simultaneous determination of oxidized and reduced plasma aminothiols using coulometric electrochemical detection. J Nutr Biochem. 1999;10(8):490–7. doi: 10.1016/S0955-2863(99)00033-9.
    1. Vester B, Rasmussen K. High performance liquid chromatography method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem. 1991;29(9):549–54.
    1. Probst R, Brandl R, Blumke M, Neumeier D. Stabilization of homocysteine concentration in whole blood. Clin Chem. 1998;44(7):1567–9.
    1. Collins AR, Dobson VL, Dusinska M, Kennedy G, Stetina R. The comet assay: what can it really tell us? Mutat Res. 1997;375(2):183–93. doi: 10.1016/S0027-5107(97)00013-4.
    1. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175(1):184–91. doi: 10.1016/0014-4827(88)90265-0.
    1. Julious S. Sample size of 12 per group rue of thumb for a pilot study. Pharm Stat. 2005;4:287–91. doi: 10.1002/pst.185.
    1. Muthen LK, Muthen BO. Mplus User's Guide 6th Edition. Los Angeles: Muthen and Muthen; 1998.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2. Hillsdale: L. Erlbaum Associates; 1988.
    1. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347(5):314–21. doi: 10.1056/NEJMoa013171.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren